These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 32416212)

  • 1. Cytokines in inflammatory bowel diseases - Update 2020.
    Leppkes M; Neurath MF
    Pharmacol Res; 2020 Aug; 158():104835. PubMed ID: 32416212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
    Dharmani P; Chadee K
    Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory Bowel Disease Drugs: A Focus on Autophagy.
    Hooper KM; Barlow PG; Stevens C; Henderson P
    J Crohns Colitis; 2017 Jan; 11(1):118-127. PubMed ID: 27381462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
    Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
    Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging immunological targets in inflammatory bowel disease.
    Monteleone G; Pallone F; MacDonald TT
    Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease.
    Furfaro F; Alfarone L; Gilardi D; Correale C; Allocca M; Fiorino G; Argollo M; Zilli A; Zacharopoulou E; Loy L; Roda G; Danese S
    Curr Drug Targets; 2021; 22(7):760-769. PubMed ID: 33475057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases.
    De Nitto D; Sarra M; Cupi ML; Pallone F; Monteleone G
    Curr Pharm Des; 2010; 16(33):3656-60. PubMed ID: 21128900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting IL-23 for IBD: Rationale and Progress to Date.
    Vuyyuru SK; Shackelton LM; Hanzel J; Ma C; Jairath V; Feagan BG
    Drugs; 2023 Jul; 83(10):873-891. PubMed ID: 37266801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune system alterations in patients with inflammatory bowel disease during remission.
    Sventoraityte J; Zvirbliene A; Kiudelis G; Zalinkevicius R; Zvirbliene A; Praskevicius A; Kupcinskas L; Tamosiūnas V
    Medicina (Kaunas); 2008; 44(1):27-33. PubMed ID: 18277086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases.
    Strober W; Fuss IJ
    Gastroenterology; 2011 May; 140(6):1756-1767. PubMed ID: 21530742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of IL-23: What is in the Pipeline?
    Parigi TL; Iacucci M; Ghosh S
    J Crohns Colitis; 2022 May; 16(Supplement_2):ii64-ii72. PubMed ID: 35553666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone density improves with disease remission in patients with inflammatory bowel disease.
    Reffitt DM; Meenan J; Sanderson JD; Jugdaohsingh R; Powell JJ; Thompson RP
    Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1267-73. PubMed ID: 14624148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
    Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for targeting cytokines in inflammatory bowel disease.
    Neurath MF
    Nat Rev Immunol; 2024 Aug; 24(8):559-576. PubMed ID: 38486124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytokines in the pathogenesis of inflammatory bowel diseases].
    José León A; Garrote JA; Arranz E
    Med Clin (Barc); 2006 Jun; 127(4):145-52. PubMed ID: 16831396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of inflammatory bowel disease (IBD).
    Pithadia AB; Jain S
    Pharmacol Rep; 2011; 63(3):629-42. PubMed ID: 21857074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical management of specific clinical presentations.
    Bitton A; Peppercorn MA
    Gastroenterol Clin North Am; 1995 Sep; 24(3):541-58. PubMed ID: 8809235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.
    de Mattos BR; Garcia MP; Nogueira JB; Paiatto LN; Albuquerque CG; Souza CL; Fernandes LG; Tamashiro WM; Simioni PU
    Mediators Inflamm; 2015; 2015():493012. PubMed ID: 26339135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.